PMCPA Case Analysis

Over 2,000 real rulings β€” analysed for what they mean to your team. Published every day.

All Cases PMCPA Case of the Week PMCPA Cases

Showing 1914 cases

2022
CASE
AUTH/3715/11/22 GlaxoSmithKline

GSK: ERS 2022 symposium highlights video ruled misleading on NMA-based COPD comparisons (Trelegy) (AUTH/3715/11/22)

A Trelegy promotional video summarising an ERS 2022 symposium overstated statistical significance in NMA comparisons on COPD exacerbations, leading to breaches for…

2023
CASE
AUTH/3763/4/23 Novo Nordisk

Novo Nordisk: delayed Disclosure UK reporting and weak governance over sponsored third-party materials (AUTH/3763/4/23)

Novo Nordisk failed to disclose some transfers of value on time and did not disclose others at all due to HCO misclassification.…

2023
CASE
AUTH/3784/6/23 AstraZeneca

AstraZeneca: employees’ LinkedIn β€˜likes’ treated as public promotion of POMs (AUTH/3784/6/23)

A third-party LinkedIn post named four AstraZeneca oncology POMs. UK-based AstraZeneca employees β€˜liked’ it, which the Panel said disseminated promotional content to…

2023
CASE
AUTH/3728/1/23 Bristol-Myers Squibb ⭐ Case of the Week

AUTH/3728/1/23: Complainant v Bristol Myers Squibb – alleged promotion of Zeposia (ozanimod hydrochloride) (No breach / not within scope)

PMCPA case AUTH/3728/1/23: complaint alleging promotion of Zeposia (ozanimod hydrochloride) against Bristol Myers Squibb. Outcome: no breach; matter not within the scope…

2023
CASE
AUTH/3816/7/23 Stirling Anglian

AUTH/3816/7/23: Stirling Anglian breached Clause 12.9 after omitting adverse event reporting statement from Acepiro banner ad

Acepiro (acetylcysteine) banner ad on a learned society homepage lacked the required adverse event reporting statement within the ad itself. Linking to…

2023
CASE
AUTH/3776/6/23 Daiichi-Sankyo UK

AUTH/3776/6/23: Complainant v Daiichi Sankyo β€” patient organisation cholesterol programme (no breach)

Complaint alleged a patient organisation guideline was promotional for Nilemdo/Nustendi and lacked contraindication detail, PI and certification. Panel found Daiichi Sankyo not…

2023
CASE
AUTH/3808/8/23 Sun Pharma

AUTH/3808/8/23: Complainant v Sun Pharma β€” ability to contact the company (No breach)

Complaint alleged Sun Pharma phone numbers and website were not functional, potentially affecting patient queries and side effect reporting. Panel found one…

2024
CASE
AUTH/3905/5/24 Organon

AUTH/3905/5/24: Nexplanon ad and linked website challenged for missing contraindications (no breach)

Organon’s Nexplanon ad on a closed doctors’ network was alleged to omit key contraindications and cancer-risk context. Panel found the ad and…

2024
CASE
AUTH/3920/6/24 AstraZeneca ⭐ Case of the Week

AUTH/3920/6/24: Complainant v AstraZeneca β€” LinkedIn β€˜Experience’ section references to Enhertu (no breach)

Complaint alleged a senior employee’s LinkedIn β€˜Experience’ section promoted Enhertu to the public and off-label, using terms like β€œblockbuster” and β€œnew”. Panel…

2024
CASE
AUTH/3887/4/24 Cipla

Cipla: failure to evidence HCP interaction records led to Clause 5.1 breach (AUTH/3887/4/24)

PMCPA found Cipla failed to evidence records of representative interactions with HCPs for nearly two years (Aug 2022–Jul 2024), breaching Clause 5.1…

2024
CASE
AUTH/3915/5/24 GlaxoSmithKline

GSK breach for unclear sponsorship disclosure on third-party conference webpages (AUTH/3915/5/24)

GSK was found in breach of Clause 25.3 twice after sponsorship of a healthcare organisation’s conference was not clearly acknowledged from the…

Recordati Pharmaceuticals

Recordati: Tradorec XL β€˜Dear Dispensary Manager’ letter and MHRA reference

A hospital pharmacy manager complained about a Recordati letter for Tradorec XL citing MHRA advice on brand prescribing and substitution. The Panel…

2008
CASE
AUTH/2111/3/08 Gamble ⭐ Case of the Week

Procter & Gamble and Sanofi-Aventis: Actonel Combi promotional email and prior consent (AUTH/2111/3/08 & AUTH/2112/3/08)

A GP complained about an allegedly unsolicited promotional email for Actonel Combi. The Panel found the recipient had given prior, fully informed…

2008
CASE
Chugai

Roche and Chugai voluntary admission: tocilizumab media release claims of superiority over methotrexate

Roche and Chugai voluntarily admitted a UK media release about unlicensed tocilizumab could be factually incorrect when read alone. The Panel found…

2008
CASE
AUTH/2144/7/08 Syner-Med

AUTH/2144/7/08 Nurse v Syner-Med: Question at a meeting (no breach)

A nurse complained that discussion at a Syner-Med sponsored symposium implied an EpiPen could replace cardio-pulmonary resuscitation for IV iron reactions. The…

Ask questions about any PMCPA case

Anzal, our PMCPA rulings expert, has knowledge of over 2,000 published cases β€” ask about precedents, clauses, and how they apply to your situation.

⭐ Flagship Programme

AQP Flagship Path — the complete UK ABPI signatory programme

12 modules. 12 weeks. Final Signatory readiness. The industry standard for ABPI Code signatories — £995 + VAT.

Enrol — AQP Path Learn more

📰 Weekly PMCPA Case Breakdown

One real case. One key lesson. Every week β€” free.

Subscribe Free
🎓 AQP Training